[Biomarkers in inflammatory bowel diseases]

Xavier Roblin; Alaric Cavaille; Léa Clavel; Stéphane Paul

doi:10.1016/j.lpm.2013.11.004

[Biomarkers in inflammatory bowel diseases]

Presse Med. 2014 Jan;43(1):66-73. doi: 10.1016/j.lpm.2013.11.004. Epub 2013 Dec 27.

[Article in French]

Authors

Xavier Roblin¹, Alaric Cavaille², Léa Clavel³, Stéphane Paul⁴

Affiliations

¹ CHU de Saint-Étienne, hôpital Nord, service de gastro-entérologie, 42277 Saint-Priest-en-Jarez, France. Electronic address: xavier.roblin@chu-st-etienne.fr.
² CHU de Saint-Étienne, hôpital Nord, service de chirurgie digestive, 42277 Saint-Priest-en-Jarez, France.
³ CHU de Saint-Étienne, hôpital Nord, service de gastro-entérologie, 42277 Saint-Priest-en-Jarez, France.
⁴ CHU de Saint-Étienne, hôpital Nord, immunopharmacologie, 42277 Saint-Priest-en-Jarez, France.

PMID: 24373717
DOI: 10.1016/j.lpm.2013.11.004

Abstract

Fecal calprotectine is of interest for diagnosis of IBD at the beginning. CRP and fecal calprotectine are predictive of long-term response in patients treated by anti-TNF therapy. Trough levels of anti-TNF are associated to clinical remission and mucosal healing. Detectable antibodies to anti-TNF are associated with lower response to treatment. Interventional studies are waiting before optimization of treatment in function of biomarkers. Trough levels of anti-TNF help to modify our treatment (optimization or de-escalation).

Publication types

English Abstract
Review

MeSH terms

Biomarkers / analysis*
C-Reactive Protein / metabolism
Feces / chemistry
Humans
Inflammatory Bowel Diseases / blood
Inflammatory Bowel Diseases / diagnosis*
Inflammatory Bowel Diseases / drug therapy
Leukocyte L1 Antigen Complex / analysis
Treatment Outcome
Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

Biomarkers
Leukocyte L1 Antigen Complex
Tumor Necrosis Factor-alpha
C-Reactive Protein